December 2017

New Product - Monurol

Monurol (fosfomycin (trometamol)) inhibits the phosphoenolpyruvate transferase enzyme, irreversibly blocking the condensation of uridine diphosphate-N-acetylglucosamine with p-enolpyruvate. Fosfomycin has a mainly bactericidal action. Monurol is indicated only for the treatment of acute uncomplicated lower urinary tract infections (acute cystitis) in females over 12 years of age caused by the following susceptible pathogens: Enterobacteriaceae (including Escherichia coli), Enterococcus faecalis. Monurol is not indicated for the treatment of pyelonephritis or perinephric abscess or where resistance is likely (previous treatment failure, infection due to nonsusceptible organism). Monurol is contraindicated with severe renal insufficiency (creatinine clearance < 10 mL/minute), haemofiltration, haemodialysis or peritoneal dialysis. Monurol granules for oral solution (fosfomycin 3 g) are available in one single use sachet.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au